Clinical Trials Logo

Polyuria clinical trials

View clinical trials related to Polyuria.

Filter by:

NCT ID: NCT05890690 Recruiting - Primary Polydipsia Clinical Trials

Plasma Copeptin in Response to Oral Urea in Healthy Adults and Patients With Polyuria-polydipsia Syndrome

URANOS
Start date: June 2, 2023
Phase: N/A
Study type: Interventional

The aim of this study is to investigate whether oral urea stimulates copeptin release and, if so, whether it may provide a novel diagnostic test in the differentiation between AVP-D (Arginine vasopressin deficiency) and PP (primary polydipsia).

NCT ID: NCT05300308 Recruiting - Nocturia Clinical Trials

Lymphoedema and Nocturia/Nocturnal Polyuria After Pelvic LND for Urogenital Cancer

UroLymph
Start date: January 21, 2022
Phase:
Study type: Observational

After the treatment of urogenital cancer, a person may develop lymphoedema of the leg(s) and/ or midline region. Clinical symptoms include abnormal tissue swelling, sensation of limb heaviness, erythema, pain, and impaired limb function. Lymphoedema can have a negative impact on quality of life (QoL) and the impact of lymphoedema on the cancer treatment decision making process is underestimated. A limited number of studies have evaluated the incidence rate of midline and leg lymphoedema after surgery for urogenital cancers and have investigated the prognostic variables. In addition, to the researchers knowledge, no evidence exists regarding which (combination of) clinical measuring methods are most sensitive to detect early lymphoedema at the lower limbs after the treatment of urogenital cancer. Therefore, in this prospective observational study, the epidemiology (i.e. incidence/ prevalence rate and prognostic variables) and the detection methods of lower limb lymphoedema after pelvic lymph node dissection for urogenital cancer will be investigated. Additionally, the epidemiology of nocturia and nocturnal polyuria will be studied (since this information is also missing in literature).

NCT ID: NCT05266157 Recruiting - Clinical trials for Lower Limb Lymphedema

Lymphoedema and Nocturia/ Nocturnal Polyuria After Pelvic Lymph Node Dissection for Urogenital Cancer

UroLymph
Start date: January 21, 2022
Phase: N/A
Study type: Interventional

After the treatment of urogenital cancer, a person may develop lymphoedema of the leg(s) and/ or midline region. Lymphoedema is the result of a dysfunction in the lymphatic system and is characterized by excessive retention of lymphatic fluid in the interstitial compartment, adipose deposition and chronic tissue inflammation resulting in fibrosis. Clinical symptoms include abnormal tissue swelling, sensation of limb heaviness, erythema, pain, and impaired limb function. The added value of manual lymph drainage, applied in patients with mild (early) lower limb lymphoedema and in addition to skin care, exercises and a compression stocking, has never been investigated. Therefore, the objective of this randomised controlled pilot trial is to investigate the feasibility of a trial about the added value of manual lymph drainage (to skin care, exercises and wearing compression stocking) in patients with mild (early) lower limb lymphoedema. In fact, the investigators want to determine the sample size for a trial investigating the effectiveness of MLD and want to investigate the feasibility of the study design.

NCT ID: NCT04526340 Completed - Nocturia Clinical Trials

Food and Salt Handling in Diuresis

Start date: June 24, 2019
Phase: N/A
Study type: Interventional
Read more »
NCT ID: NCT04520477 Completed - Nocturnal Polyuria Clinical Trials

Watershift - Pilot Study

WATERSHIFT
Start date: July 1, 2018
Phase: N/A
Study type: Interventional
Read more »
NCT ID: NCT04329975 Completed - Clinical trials for Nocturia Due to Nocturnal Polyuria

Specified Drug Use-results Survey (Long-term Use) on MINIRINMELT® OD Tablet (Nocturia)

NOC01
Start date: May 19, 2020
Phase:
Study type: Observational [Patient Registry]

To investigate the incidence and risk factors of desmopressin-induced hyponatremia during long-term treatment (1 year [52 weeks]) of MINIRINMELT orally disintegrating (OD) tablets 25μg/50μg (drug) for nocturia caused by nocturnal polyuria in men in daily clinical practice, and to confirm the compliance with proper use of this drug in clinical practice and to investigate the effectiveness of risk minimization activities.

NCT ID: NCT04125186 Completed - Nocturnal Polyuria Clinical Trials

A Cross-Functional, Population-Representative, Web-Based, Epidemiologic Study to Estimate the Prevalence and Burden of Nocturia Due to Nocturnal Polyuria in the US

Start date: July 22, 2019
Phase:
Study type: Observational

To estimate the prevalence of nocturia due to nocturnal polyuria (NP) in the US and describe the demographic and clinical characteristics as well as the burden of illness in participants with nocturia due to NP.

NCT ID: NCT04049019 Completed - Nocturnal Enuresis Clinical Trials

Biomarkers in Urine for Children With Monosymptomatic Nocturnal Enuresis and Nocturnal Polyuria

Start date: August 1, 2019
Phase: N/A
Study type: Interventional

The aim of the study is to identify protein markers in relation to the enuresis related nocturnal polyuria by using mass spectrometry on nocturnal urine samples. A biomarker for nocturnal polyuria would simplify an important part of the clinical characterization of enuresis patients.

NCT ID: NCT03858439 Completed - Clinical trials for Autosomal Dominant Polycystic Kidney

Dietary Intervention in ADPKD on Tolvaptan

DIAT
Start date: June 6, 2019
Phase: N/A
Study type: Interventional

Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited renal disorder. Tolvaptan has been approved in Canada as a treatment for ADPKD. Tolvaptan is an arginine vasopressin receptor antagonist which has been shown to decrease the progression of ADPKD. The main side effect of this treatment is increased urine output which leads to cessation of therapy in about 20% of patients. Low solute (low sodium, low protein) diet may alleviate this side effect. This is a single arm before / after study of dietary intervention on urine output and quality of life in ADPKD patients on a stable dose of tolvaptan.

NCT ID: NCT03844217 Completed - Clinical trials for Polyuria-polydipsia Syndrome

Copeptin After an Oral Stimulation With Macimorelin in Healthy Volunteers

Macicop
Start date: March 7, 2019
Phase: N/A
Study type: Interventional

This study investigates stimulation of the posterior pituitary gland by oral Macimorelin (a ghrelin receptor Agonist) to be a novel diagnostic test in the polyuria-polydipsia syndrome.